Bioject Announces New Supply Agreement with Merck Serono.

PORTLAND, Ore. -- Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems, today announced that it has entered into a three-year supply agreement with Merck Serono, a division of Merck KGaA of Darmstadt, Germany, for the delivery of the cool.click[TM] and Serojet[TM] spring-powered needle-free device for use with Merck Serono's recombinant human growth hormone drugs.

"We are pleased to enter into this new agreement with Merck Serono, which is the continuation of our successful relationship with them," said Ralph Makar, newly appointed President and CEO of Bioject. "Merck Serono has been an excellent partner and we appreciate the confidence Merck Serono has in our proprietary needle-free technology. We look forward to continuing to supply them with our value-added spring-powered device and disposables for their recombinant human growth hormone drugs." Makar further commented, "We understand the importance and advantages of providing our needle-free technology for the delivery of such compounds as growth hormones and we are looking forward to expanding our technology in other fields."

Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.

For more information on Bioject, visit www.bioject.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Bioject's expectations with respect to expanding the use of its needle-free technology in other fields. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include, without limitation, the risk that the Company's products will not be accepted by the market, the risk that the Company will be unable to successfully develop and negotiate new strategic relationships or maintain existing relationships, uncertainties related to the time required for the Company to complete research and development, obtain necessary clinical data and government clearances, and the risk that the Company may be unable to comply with the extensive government regulations applicable to Bioject's business. Readers of this press release are referred to the Company's filings with the Securities and Exchange Commission, including the Company's reports on Form 10-K and Forms 10-Q for further discussions of factors that could affect the Company's business and its future results. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. The Company assumes no obligation to update forward-looking statements if conditions or management's estimates or opinions should change.